Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M
Research suggests it may influence skin barrier function and fibroblast activity, though human clinical data remains limited compared to other peptide therapeutics
First developed in the early 2000s to treat type 2 diabetes by mimicking the action of the naturally occurring hormone glucagon-like peptide 1, GLP-1 receptor agonists have since been shown to have a positive and significant impact on obesity, other medical conditions and biological functions
Looking ahead, with a deeper understanding of the pathogenesis of AD and the continuous advancement of drug development technology, peptide drugs will have a broader prospect in the treatment of AD
GLP-1 medicines can change how hungry you feel
In studies where patients tapered off slowly, hunger hormones rose more gently, and weight regain was smaller